| Fouad M Abbas, | |
|
2411 W Belvedere Ave, Suite 206, Baltimore, MD 21215-5228 | |
| (410) 601-9030 | |
| Not Available |
| Full Name | Fouad M Abbas |
|---|---|
| Gender | Male |
| Speciality | Gynecological Oncology |
| Experience | 38 Years |
| Location | 2411 W Belvedere Ave, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023087699 | NPI | - | NPPES |
| 122MI1215 | Other | MD | MEDICARE ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D0038972 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sinai Hospital Of Baltimore | Baltimore, MD | Hospital |
| Northwest Hospital Center | Randallstown, MD | Hospital |
| University Of Md Baltimore Washington Medical Center | Glen burnie, MD | Hospital |
| Frederick Health Hospital | Frederick, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sinai Hospital Of Baltimore, Inc | 0941112346 | 333 |
News Archive
Our daily routines can become so ingrained that we perform them automatically, such as taking the same route to work every day. Some behaviors, such as smoking or biting your fingernails, become so habitual that we can't stop even if we want to.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
Democrats are going on the offensive and using the controversial Republican plan to overhaul Medicare to seize the political moment.
Accu-Break Pharmaceuticals, Inc. announced today that it has entered into a development and license agreement with Alembic Pharmaceuticals Limited of Gujarat, India to develop new brand products that will use ABP's innovative Accu-Break tablet technologies.
› Verified 6 days ago
| Entity Name | Sinai Hospital Of Baltimore, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043235666 PECOS PAC ID: 0941112346 Enrollment ID: O20031104000353 |
News Archive
Our daily routines can become so ingrained that we perform them automatically, such as taking the same route to work every day. Some behaviors, such as smoking or biting your fingernails, become so habitual that we can't stop even if we want to.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
Democrats are going on the offensive and using the controversial Republican plan to overhaul Medicare to seize the political moment.
Accu-Break Pharmaceuticals, Inc. announced today that it has entered into a development and license agreement with Alembic Pharmaceuticals Limited of Gujarat, India to develop new brand products that will use ABP's innovative Accu-Break tablet technologies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fouad M Abbas, 2411 W Belvedere Ave, Suite 206, Baltimore, MD 21215-5228 Ph: (410) 601-9030 | Fouad M Abbas, 2411 W Belvedere Ave, Suite 206, Baltimore, MD 21215-5228 Ph: (410) 601-9030 |
News Archive
Our daily routines can become so ingrained that we perform them automatically, such as taking the same route to work every day. Some behaviors, such as smoking or biting your fingernails, become so habitual that we can't stop even if we want to.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
Democrats are going on the offensive and using the controversial Republican plan to overhaul Medicare to seize the political moment.
Accu-Break Pharmaceuticals, Inc. announced today that it has entered into a development and license agreement with Alembic Pharmaceuticals Limited of Gujarat, India to develop new brand products that will use ABP's innovative Accu-Break tablet technologies.
› Verified 6 days ago
Miss Elizabeth Unique Morris, MSN, WHNP-BC Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 330 N Howard St, Baltimore, MD 21201 Phone: 410-576-1414 | |
Christine E. O Connor, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 227 Saint Paul St, 6th Floor, Baltimore, MD 21202 Phone: 410-332-9002 Fax: 410-783-5880 | |
Fateh Hraky Sr., Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3001 S Hanover St, Suite 301, Baltimore, MD 21225 Phone: 410-350-0800 | |
Joyce A Bonsu, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3449 Wilkens Ave Ste 305, Baltimore, MD 21229 Phone: 410-644-2582 Fax: 410-644-6232 | |
Dr. Ginny M Merryman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6569 N Charles St, Suite 501, Baltimore, MD 21204 Phone: 410-938-8960 Fax: 410-583-9770 | |
Dr. Golsa Mirmiran Yazdy, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave Bldg A1, Baltimore, MD 21224 Phone: 410-550-0337 Fax: 410-550-0196 |